Segesterone acetate/ethinylestradiol

Segesterone acetate/ethinylestradiol

Ethinylestradiol (top) and segesterone acetate (bottom)
Combination of
Segesterone acetate	Progestogen
Ethinylestradiol	Estrogen
Clinical data
Trade names	Annovera
Other names	EE/SGA; EE/SA
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604032
License data	US DailyMed: Segesterone_acetate_and_ethinyl_estradiol
Routes of administration	Intravaginal
ATC code	None
Legal status
Legal status	US: ℞-only
Identifiers
KEGG	D11654

Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen. It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use. Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.

See also

• Combined injectable birth control § Available forms
• List of combined sex-hormonal preparations

External links

• "Segesterone acetate". Drug Information Portal. U.S. National Library of Medicine.
• "Ethinylestradiol". Drug Information Portal. U.S. National Library of Medicine.